Cancer Genetics Testing Firm NeoGenomics Eyes $7.8M from Public Offering of Stock | GenomeWeb

NEW YORK (GenomeWeb News) – NeoGenomics today announced the public offering of 3.15 million shares of its common stock at $3.00 per share.

The Ft. Myers, Fla.-based firm which specializes in cancer genetic testing, is selling 2.85 million shares, while a shareholder, the Mary S. Dent Gifting Trust, will sell 300,000 shares.

NeoGenomics expects to raise $7.8 million in net proceeds from the offering. It will not receive any proceeds from Mary S. Dent's sale of its shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.